Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol.

@article{Hiratsuka2007CharacterizationOH,
  title={Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol.},
  author={Masahiro Hiratsuka and Yudai Hinai and Takamitsu Sasaki and Yumiko Konno and Kenichi Imagawa and Masaaki Ishikawa and Michinao Mizugaki},
  journal={Drug metabolism and disposition: the biological fate of chemicals},
  year={2007},
  volume={35 10},
  pages={1730-2}
}
Cilostazol (OPC-13013; 6-[4-(1-cyclohexl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone) is widely used as an antiplatelet vasodilator agent. In vitro, the hydroxylation of the quinone moiety of cilostazol to OPC-13326 [6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-4-hydroxy-2(1H)-quinolinone], is the predominant route, and the hydroxylation of the hexane moiety to OPC-13217 is the second most predominant route. This study was carried out to identify and kinetically… CONTINUE READING